These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 17497245)
1. Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites. El-Kabbani O; Podjarny A Cell Mol Life Sci; 2007 Aug; 64(15):1970-8. PubMed ID: 17497245 [TBL] [Abstract][Full Text] [Related]
2. Mechanism of human aldehyde reductase: characterization of the active site pocket. Barski OA; Gabbay KH; Grimshaw CE; Bohren KM Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785 [TBL] [Abstract][Full Text] [Related]
3. All in the family: aldose reductase and closely related aldo-keto reductases. Petrash JM Cell Mol Life Sci; 2004 Apr; 61(7-8):737-49. PubMed ID: 15094999 [TBL] [Abstract][Full Text] [Related]
4. Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. Carbone V; Zhao HT; Chung R; Endo S; Hara A; El-Kabbani O Bioorg Med Chem; 2009 Feb; 17(3):1244-50. PubMed ID: 19121944 [TBL] [Abstract][Full Text] [Related]
5. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites. El-Kabbani O; Old SE; Ginell SL; Carper DA Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777 [TBL] [Abstract][Full Text] [Related]
6. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111). Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137 [TBL] [Abstract][Full Text] [Related]
7. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. El-Kabbani O; Wilson DK; Petrash M; Quiocho FA Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955 [TBL] [Abstract][Full Text] [Related]
8. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153 [TBL] [Abstract][Full Text] [Related]
9. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227 [TBL] [Abstract][Full Text] [Related]
10. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex. Petrova T; Steuber H; Hazemann I; Cousido-Siah A; Mitschler A; Chung R; Oka M; Klebe G; El-Kabbani O; Joachimiak A; Podjarny A J Med Chem; 2005 Sep; 48(18):5659-65. PubMed ID: 16134934 [TBL] [Abstract][Full Text] [Related]
11. Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features. Steuber H; Heine A; Podjarny A; Klebe G J Mol Biol; 2008 Jun; 379(5):991-1016. PubMed ID: 18495158 [TBL] [Abstract][Full Text] [Related]
12. Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis. Hohman TC; El-Kabbani O; Malamas MS; Lai K; Putilina T; McGowan MH; Wane YQ; Carper DA Eur J Biochem; 1998 Sep; 256(2):310-6. PubMed ID: 9760169 [TBL] [Abstract][Full Text] [Related]
13. Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis. Matsunaga T; Endo S; Soda M; Zhao HT; El-Kabbani O; Tajima K; Hara A Biochem Biophys Res Commun; 2009 Nov; 389(1):128-32. PubMed ID: 19706287 [TBL] [Abstract][Full Text] [Related]
14. In Search of Differential Inhibitors of Aldose Reductase. Balestri F; Moschini R; Mura U; Cappiello M; Del Corso A Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454074 [TBL] [Abstract][Full Text] [Related]
15. Aldose Reductase and the Polyol Pathway in Schwann Cells: Old and New Problems. Niimi N; Yako H; Takaku S; Chung SK; Sango K Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494154 [TBL] [Abstract][Full Text] [Related]
16. Kinetic characteristics of ZENECA ZD5522, a potent inhibitor of human and bovine lens aldose reductase. Cook PN; Ward WH; Petrash JM; Mirrlees DJ; Sennitt CM; Carey F; Preston J; Brittain DR; Tuffin DP; Howe R Biochem Pharmacol; 1995 Apr; 49(8):1043-9. PubMed ID: 7748183 [TBL] [Abstract][Full Text] [Related]
17. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening. Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382 [TBL] [Abstract][Full Text] [Related]
18. Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications. Vander Jagt DL; Hassebrook RK; Hunsaker LA; Brown WM; Royer RE Chem Biol Interact; 2001 Jan; 130-132(1-3):549-62. PubMed ID: 11306074 [TBL] [Abstract][Full Text] [Related]
19. Benzoxazinone-thiosemicarbazones as antidiabetic leads via aldose reductase inhibition: Synthesis, biological screening and molecular docking study. Shehzad MT; Imran A; Njateng GSS; Hameed A; Islam M; Al-Rashida M; Uroos M; Asari A; Shafiq Z; Iqbal J Bioorg Chem; 2019 Jun; 87():857-866. PubMed ID: 30551808 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10. Endo S; Hu D; Suyama M; Matsunaga T; Sugimoto K; Matsuya Y; El-Kabbani O; Kuwata K; Hara A; Kitade Y; Toyooka N Bioorg Med Chem; 2013 Nov; 21(21):6378-84. PubMed ID: 24071447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]